

## Urgent Field Safety Notice Recall / Replacement

### Humatex ASO

06.11.2017

**Attention:**

Distributors of HUMAN and end users of:

**Details on affected devices**

Cat. No. 40060, Lot 16008, 17004, 17005

**Description of the problem:**

During internal evaluations after a customer complaint we noticed that the above mentioned batches led to a agglutination upon reaction of the latex reagent with several negative patient sera, although the negative control material provided with the complete kit (Cat. Nos 40062, 40063) did not show agglutination. Thus the affected lots may provide false positive patient results which are not recognized by the negative control.

HUMAN thus recommends not using the above mentioned product lots anymore.

**Advice on action to be taken by:**Distributor:

Please inform the end user of the above product lots about the problem described here, based on this customer information.

Please fill in the attached reply form confirming receipt and send it to [customer-support@human.de](mailto:customer-support@human.de). Kits still on stock of the distributor or the end user will be replaced as claimed in the Reply form.

User:

End users should stop using the affected lot and confirm receipt of the customer information to the local distributor. Any suspicious positive results (e.g. not in agreement with other information of patient status) should be reconsidered.

**Transmission of this Field Safety Notice**

This notice needs to be passed on all those who need to be aware within your organization or to any organization where the potentially affected devices have been transferred.

Please transfer this notice to other organizations on which this action has an impact.

Please maintain awareness on this notice and resulting action for an appropriate period to ensure effectiveness of the corrective action.

The Federal Institute for Drugs and Medical Devices (BfArM) and other National Competent Authorities of European countries, which are affected by the recall, received a copy of this urgent field safety notice


**Contact reference person:**

(for distributors only. Distributors should provide their own detailed contact information to their end users):

Sonja, Simonovic  
Customer Support & Applications  
e-mail: [customer-support@human.de](mailto:customer-support@human.de)  
Telephone: +49-6122-9988-383


We regret the inconvenience.

With kind regards,



Sonja Simonovic

Customer Support & Applications



Attachment  
Reply Form

## Reply Form

### Urgent Field Safety Notice

**For Humatex ASO  
Cat. No. 40060, Lot 16008, 17004, 17005**

**Please return** by e-mail this filled in and signed reply form latest until November 9th, 2017 to  
E-mail address: customer-support@human.de

**For distributors in the European Union:**

- Please attach the Customer Information in your national language, which you have sent out to your end customers, as Human will be approached by your national Competent Authority to provide this.

I confirm receipt of this customer information and have informed all end customers, who have obtained the affected lot, in writing about the problem and the HUMAN recommendations.

I confirm that the affected kits in my stock and those kits, which will be returned from my customers, will be destroyed according to local regulations.

Number of kits of REF 40060, lot 16008 to be replaced: \_\_\_\_\_

Number of kits of REF 40060, lot 17004 to be replaced: \_\_\_\_\_

Number of kits of REF 40060, lot 17005 to be replaced: \_\_\_\_\_

Date: \_\_\_\_\_

Company: \_\_\_\_\_

Name: \_\_\_\_\_

Signature: \_\_\_\_\_

## Urgent Field Safety Notice Recall / Replacement

### Humatex ASO

06.11.2017

**Attention:**

Distributors of HUMAN and end users of:

**Details on affected devices**

Cat. No. 40062 Lots 16004, 16005, 17003

**Description of the problem:**

During internal evaluations after a customer complaint we noticed that the above mentioned batches led to an agglutination upon reaction of the latex reagent with several negative patient sera, although the negative control material provided with the kit did not show agglutination. Thus the affected lots may provide false positive patient results which are not recognized by the negative control.

HUMAN thus recommends not using the above mentioned product lots anymore.

**Advice on action to be taken by:**Distributor:

Please inform the end user of the above product lots about the problem described here, based on this customer information.

Please fill in the attached reply form confirming receipt and send it to [support@human.de](mailto:support@human.de). Kits still on stock of the distributor or the end user will be replaced as claimed in the Reply form.

User:

End users should stop using the affected lot and confirm receipt of the customer information to the local distributor. Any suspicious positive results (e.g. not in agreement with other information of patient status) should be reconsidered.

**Transmission of this Field Safety Notice**

This notice needs to be passed on all those who need to be aware within your organization or to any organization where the potentially affected devices have been transferred.

Please transfer this notice to other organizations on which this action has an impact.

Please maintain awareness on this notice and resulting action for an appropriate period to ensure effectiveness of the corrective action.

The Federal Institute for Drugs and Medical Devices (BfArM) and other National Competent Authorities of European countries, which are affected by the recall, received a copy of this urgent field safety notice


**Contact reference person:**

(for distributors only. Distributors should provide their own detailed contact information to their end users):

Sonja, Simonovic  
Customer Support & Applications  
e-mail: support@human.de  
Telephone: +49-6122-9988-383


We regret the inconvenience.

With kind regards,



Sonja Simonovic

Customer Support & Applications



Attachment  
Reply Form

## Reply Form

### Urgent Field Safety Notice

**For Humatex ASO  
Cat. No. 40062 , Lot 16004, 16005, 17003**

**Please return** by e-mail this filled in and signed reply form latest until November 20th, 2017 to  
E-mail address: support@human.de

I confirm receipt of this customer information and have informed all end customers, who have obtained the affected lot, in writing about the problem and the HUMAN recommendations.

I confirm that the affected kits in my stock and those kits, which will be returned from my customers, will be destroyed according to local regulations.

Number of kits of REF 40062, lot 16004 to be replaced: \_\_\_\_\_

Number of kits of REF 40062, lot 16005 to be replaced: \_\_\_\_\_

Number of kits of REF 40062, lot 17003 to be replaced: \_\_\_\_\_

Date: \_\_\_\_\_

Company: \_\_\_\_\_

Name: \_\_\_\_\_

Signature: \_\_\_\_\_

## Urgent Field Safety Notice Recall / Replacement

### Humatex ASO

06.11.2017

**Attention:**

Distributors of HUMAN and end users of:

**Details on affected devices**

Cat. No. 40063, Lot. 16009 - 16013, 17005 &amp; 17006

**Description of the problem:**

During internal evaluations after a customer complaint we noticed that the above mentioned batches led to an agglutination upon reaction of the latex reagent with several negative patient sera, although the negative control material provided with the kit did not show agglutination. Thus the affected lots may provide false positive patient results which are not recognized by the negative control.

HUMAN thus recommends not using the above mentioned product lots anymore.

**Advice on action to be taken by:**Distributor:

Please inform the end user of the above product lots about the problem described here, based on this customer information.

Please fill in the attached reply form confirming receipt and send it to [support@human.de](mailto:support@human.de). Kits still on stock of the distributor or the end user will be replaced as claimed in the Reply form.

User:

End users should stop using the affected lot and confirm receipt of the customer information to the local distributor. Any suspicious positive results (e.g. not in agreement with other information of patient status) should be reconsidered.

**Transmission of this Field Safety Notice**

This notice needs to be passed on all those who need to be aware within your organization or to any organization where the potentially affected devices have been transferred.

Please transfer this notice to other organizations on which this action has an impact.

Please maintain awareness on this notice and resulting action for an appropriate period to ensure effectiveness of the corrective action.

The Federal Institute for Drugs and Medical Devices (BfArM) and other National Competent Authorities of European countries, which are affected by the recall, received a copy of this urgent field safety notice


**Contact reference person:**

(for distributors only. Distributors should provide their own detailed contact information to their end users):

Sonja, Simonovic  
Customer Support & Applications  
e-mail: support@human.de  
Telephone: +49-6122-9988-383


We regret the inconvenience.

With kind regards,



Sonja Simonovic

Customer Support & Applications



Attachment  
Reply Form



## Reply Form

### Urgent Field Safety Notice

**For Humatex ASO**  
**Cat. No. 40063, Lot 16009 - 16013, 17005 & 17006**

**Please return** by e-mail this filled in and signed reply form latest until November 20th, 2017 to  
E-mail address: support@human.de

**For distributors in the European Union:**

- Please attach the Customer Information in your national language, which you have sent out to your end customers, as Human will be approached by your national Competent Authority to provide this.

I confirm receipt of this customer information and have informed all end customers, who have obtained the affected lot, in writing about the problem and the HUMAN recommendations.

I confirm that the affected kits in my stock and those kits, which will be returned from my customers, will be destroyed according to local regulations.

Number of kits of REF 40063, lot 16009: \_\_\_\_\_

Number of kits of REF 40063, lot 16010: \_\_\_\_\_

Number of kits of REF 40063, lot 16011: \_\_\_\_\_

Number of kits of REF 40063, lot 16012: \_\_\_\_\_

Number of kits of REF 40063, lot 16013: \_\_\_\_\_

Number of kits of REF 40063, lot 17005: \_\_\_\_\_

Number of kits of REF 40063, lot 17006: \_\_\_\_\_

Date: \_\_\_\_\_

Company: \_\_\_\_\_

Name: \_\_\_\_\_

Signature: \_\_\_\_\_